ImmunoGen, Inc.|4Feb 7, 5:22 PM ET

Berkenblit Anna 4

4 · ImmunoGen, Inc. · Filed Feb 7, 2023

Form 4

Period: 2023-02-03

VP & Chief Medical Officer

Transactions

Award
Restricted Stock Unit
2023-02-03+42,700→ 42,700 total
Exercise: $0.00→ Common Stock (42,700 underlying)
Award
Stock Option (right to buy)
2023-02-03+256,300→ 256,300 total
Exercise: $4.66Exp: 2033-02-03→ Common Stock (256,300 underlying)
Award
Restricted Stock Unit
2023-02-03+63,400→ 63,400 total
Exercise: $0.00→ Common Stock (63,400 underlying)

Footnotes (4)

[F1]Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
[F2]The RSUs vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date.
[F3]These options vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant.
[F4]The RSUs shall vest with respect to 40% of such RSUs on the one-year anniversary of the date of grant and with respect to the remaining 60% of such RSUs on the eighteen-month anniversary of the date of grant, subject to continued service through each vesting date.

Documents

1 file